報價延遲最少15分鐘:2026/04/27 08:04 EDT
盤前時段
|
||||
|
1.74 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.67
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-35.25/-12.00
|
|
企業價值
6.73M
|
| 資產負債 |
|
每股賬面淨值
5.73
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
622.49K
|
|
每股收益
0.14
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases. |
